News
LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Thursday that the US Food and Drug Administration has approved a prefilled syringe presentation of Shingrix, GSK's Recombinant ...
GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
The Save the Children Immunisation Accelerator has opened a second round of applications, inviting organisations in Nigeria and Ethiopia to submit proposals for innovations that tackle entrenched ...
18h
GlobalData on MSNGSK’s Blenrep US comeback hindered by eye safety concernsFDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.
GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised ...
Explore more
UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.
The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...
Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to ...
Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...
Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.
The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug in combination with Viatris' Zoloft for the treatment of adults with PTSD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results